GlassScriptPhysician profile
Meaghan L Gustafson
NPI 1366223729
$2,629.98
in general payments reported to CMS, 2019-2025
22 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $1,345 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $361.08 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $345.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $307.92 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $284.64 | 2024-2025 | Repatha, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.31 | 2024-2025 | Jardiance |
| Dexcom, INC. | $160.01 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $155.02 | 2023-2025 | Trintellix |
| Glaxosmithkline, LLC. | $136.55 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $87.46 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $87.18 | 2024-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $79.02 | 2024-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $76.18 | 2023-2024 | Quviviq |
| Sumitomo Pharma America, INC. | $42.21 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $35.37 | 2024 | Xarelto |
| Pfizer INC. | $34.40 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $31.99 | 2024 | Flucelvax, Fluad |
| Kowa Pharmaceuticals America, INC. | $31.82 | 2023 | Livalo |
| Insulet Corporation | $31.67 | 2024 | Omnipod |
| Axsome Therapeutics, INC. | $31.26 | 2024-2025 | Auvelity |
| Novartis Pharmaceuticals Corporation | $19.39 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.24 | 2024 | |
| Medtronic, INC. | $16.35 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meaghan Gustafson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.